CSI Market
Sign In | Register

Portola Pharmaceuticals inc (PTLA) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access PTLA quarterly Cash Flow →
Cash flow data covering Portola Pharmaceuticals inc–Dec 31 2015 offers a view into how Dec 31 2019's cash position has developed alongside business activity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2019)
12 Months 		(Dec 31 2018) (Dec 31 2017) (Dec 31 2016) (Dec 31 2015)
Operating Activities
Income-292.88
Depreciation & amortization3.00
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Impairment of Intangible Assets, Finite-lived3.15
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase-54.68
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation52.08
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction25.37
Increase Decrease In Prepaid Expense And Other Current Assets3.81
Investment Income Amortization Of Premium-
Non Cash Interest-
Embedded Derivative Loss On Embedded Derivative-
Increase Decrease In Accrued Research And Development-0.58
Increase Decrease In Contract With Customer Liability-0.36
Allocated Share Based Compensation Expense Liability Classified Share Based Awards-
Manufacturing Process Transition Costs-
Operating Lease Cost3.22
Embedded Derivative Gain Loss On Embedded Derivative Net27.45
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts and Other Receivables-7.70
Increase (Decrease) in Accounts Payable-2.65
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities17.67
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-3.81
Other Working Capital0.00
Other Noncash Income (Expense)0.20
Other net0.00
Payments for (Proceeds from) Other Operating Activities-11.21
Discontinued operations0.00
Net Cash flow from Operating Activities-237.92
Investing Activities
Capital Expenditures-1.54
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities297.29
Short-term Investments Acq.0.00
Real Estate Investments0.00
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments-368.75
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-73.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings121.70
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock268.84
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Long Term Obligation To Collaborator-
Payments Of Long Term Obligation To Collaborator-0.98
Payments of Ordinary Dividends, Noncontrolling Interest0.00
Dividends paid0.00
Net Cash Flow from Financing Activities389.56
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-239.47
Total Cash Flow78.64
4 historic quarters locked

Sign in to unlock the full Portola Pharmaceuticals inc cash flow history.

Sign In Create Free Account

About PTLA Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License